Kuśnierczyk H, Rak J, Radzikowski C
Arch Immunol Ther Exp (Warsz). 1986;34(3):259-62.
Antitumor activity of four modified on amino sugar moiety derivatives of daunorubicin was compared with activity of two commercial preparations of the parental drug in tests against P 388 leukemia in mice. Tested analogs appeared to be similarly effective as the reference drugs, but two of them, DR-2 and DR-19, were found to be significantly less potent.
在针对小鼠P 388白血病的试验中，比较了柔红霉素四种氨基糖部分修饰衍生物的抗肿瘤活性与两种市售亲本药物制剂的活性。受试类似物似乎与参比药物同样有效，但发现其中两种，即DR - 2和DR - 19，效力明显较低。
